Tech Entrepreneur Phil Trubey Makes Sizeable Investment in CureMatch
The investment comes on the heels of San Diego Venture Group’s selection of CureMatch as a venture-ready company
SAN DIEGO, CA – June 14, 2017 –CureMatch, a digital health company that guides oncologists in the selection of advanced cancer therapies, today announced that Phil Trubey had joined a team of investors as part of a bridge round to Series A financing.
CureMatch is the only company to offer a report that guides oncologists in the selection of personalized combination therapies, using supercomputing and the latest discoveries in genomics and proteomics. CureMatch analyzes more than 4.5 million different drug combinations to find and rank the most advanced cancer treatments, customized specifically for the individual patient. The resulting report provides actionable knowledge and insight to the oncologist, facilitating the use of genomics in cancer treatment.
“I’ve been following CureMatch’s remarkable progress over the past several months, and am very impressed by their team and their unique technology,” said Phil Trubey. “I believe that this company is going to have a tremendous impact on how cancer is treated.”
“Phil and I both started web companies in San Diego from scratch, and both went public,” stated CureMatch CEO Blaise Barrelet, who founded the web analytics industry pioneer WebSideStory, which had a successful IPO in 2004. “We both believe that CureMatch has the potential to be bigger than WebSideStory and Websense.”
Phil Trubey joins other seed investors in CureMatch, including Mike Norman (San Diego Supercomputer Center), Susan Tharp (NCSA Mosaic), Analytics Ventures, Hera Fund, Blaise Barrelet (CureMatch), and many others.
CureMatch was recently selected by the San Diego Venture Group as one of its 2017 Cool Companies. SDVG’s list of Cool Companies are those determined to be “venture-ready” and among the “fastest-growing, most exciting startups in Southern California.” In the past two months, CureMatch has been featured on the KUSI Evening News in its weekly segment “Health Living”, as well as Xconomy, the San Diego Business Journal, Hatch Magazine, NBC 7 San Diego, and many other media outlets. Validation of the CureMatch technology and its core principles have been demonstrated through recent case studies and publications from CureMatch and its co-founders.
CureMatch will be showcased at the SDVG Cool Companies Reception on June 15 and at Startup Week’s Friday Night Startup Festival on June 23. CureMatch will also be present at RESI San Diego on June 19 and the BIO International Convention in San Diego on June 19-22. Later in the summer, CureMatch co-founder and UCSD oncologist Dr. Razelle Kurzrock will serve as a panelist at the Precision Medicine Leaders Summit in San Diego on August 21-24. The CureMatch team will also attend San Diego Venture Group’s Venture Summit in San Diego on August 30, and BIOCOM’s DeviceFest & Digital Health Summit in Carlsbad, CA, also on August 30.
CureMatch™, Inc., based in San Diego, is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS, and is considered by many to be the future of cancer treatment. CureMatch’s report guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient’s tumor. The CureMatch technology enables oncologists to select from millions of advanced cancer treatment options by providing actionable knowledge and insight to the oncologist. For more information, visit www.curematch.com